| + |
SCF-FBW7 | down-regulates quantity by destabilization 
polyubiquitination
|
PDCD1 |
0.2 |
| Identifier |
Residue |
Sequence |
Organism |
Cell Line |
| SIGNOR-277606 |
Lys233 |
LDFQWREkTPEPPVP |
Homo sapiens |
HEK-293 Cell |
| pmid |
sentence |
| 36104103 |
We identified FBW7 as a E3 ubiquitin ligase for PD-1 protein, in which FBW7 promotes the K48-linked polyubiquitination of PD-1 protein at Lys233 residue. |
|
| Publications: |
1 |
Organism: |
Homo Sapiens |
| + |
CDK1 | down-regulates quantity by destabilization
phosphorylation
|
PDCD1 |
0.2 |
| Identifier |
Residue |
Sequence |
Organism |
Cell Line |
| SIGNOR-277605 |
Ser261 |
PSGMGTSsPARRGSA |
Homo sapiens |
HEK-293 Cell |
| pmid |
sentence |
| 36104103 |
We demonstrated that cyclin-dependent kinase 1-mediated phosphorylation of Ser261 residue primes PD-1 protein nucleus translocation and binding with FBW7. |
|
| Publications: |
1 |
Organism: |
Homo Sapiens |
| + |
CD274 | up-regulates 
binding
|
PDCD1 |
0.935 |
| Identifier |
Residue |
Sequence |
Organism |
Cell Line |
| SIGNOR-82604 |
|
|
Homo sapiens |
T-lymphocyte |
| pmid |
sentence |
| 11015443 |
Pd-l1, was found to bind pd-1 specifically. The functional significance of this interaction has been demonstrated in t cell assays, in which engagement of pd-1 by pd-l1 leads to the inhibition of tcr-mediated lymphocyte proliferation and cytokine secretion. |
|
| Publications: |
1 |
Organism: |
Homo Sapiens |
| + |
PTPN11 | down-regulates activity
dephosphorylation
|
PDCD1 |
0.645 |
| Identifier |
Residue |
Sequence |
Organism |
Cell Line |
| SIGNOR-277052 |
|
|
Homo sapiens |
|
| pmid |
sentence |
| 32437509 |
Related to the latter notion, we recently showed that SHP2 dephosphorylates PD-1 to disassemble the PD-1:SHP2 complex ( xref ). |
|
| Publications: |
1 |
Organism: |
Homo Sapiens |
| + |
PDCD1 | up-regulates 
|
T cell exhaustion |
0.7 |
| Identifier |
Residue |
Sequence |
Organism |
Cell Line |
| SIGNOR-275413 |
|
|
Homo sapiens |
T-lymphocyte |
| pmid |
sentence |
| 28286692 |
Programmed cell death-1 (PD-1) is a major regulator of T-cell exhaustion, and blocking the PD-1 pathway restores T-cell function and improves pathogen control and tumor eradication. Immunotherapy targeting the PD-1 inhibitory receptor pathway has demonstrated significant antitumor activity. |
|
| Publications: |
1 |
Organism: |
Homo Sapiens |
| + |
PDCD1 | down-regulates activity 
|
ERK1/2 |
0.266 |
| Identifier |
Residue |
Sequence |
Organism |
Cell Line |
| SIGNOR-275411 |
|
|
Homo sapiens |
T-lymphocyte |
| pmid |
sentence |
| 22740686 |
MEK1/2 was phosphorylated and activated upon activation of T cells through TCR-CD3 and CD28, which resulted in phosphorylation of its downstream target ERK1/2, as determined by Western blotting analysis with an antibody specific for ERK1/2 phosphorylated at Thr202 and Tyr204, markers of activation. PD-1 substantially inhibited the activation of MEK1/2 and ERK1/2 |
|
| Publications: |
1 |
Organism: |
Homo Sapiens |
| + |
pembrolizumab | down-regulates activity
binding
|
PDCD1 |
0.4 |
| Identifier |
Residue |
Sequence |
Organism |
Cell Line |
| SIGNOR-259899 |
|
|
Homo sapiens |
Melanoma Cell, Non-small Cell Lung Cancer Cell |
| pmid |
sentence |
| 25685857 |
Preclinical studies described PD-1 blockade resulting in tumor growth suppression and even decreased metastasis. This has led to the development of pembrolizumab (MK-3475), a highly selective, humanized monoclonal IgG4-kappa isotype antibody against PD-1. Early clinical trials have shown high tumor response rates and long duration of effect in previously treated advanced melanoma resulting in accelerated FDA approval for the drug in this situation. Pembrolizumab has also had success in non-small cell lung cancer and is being tested in multiple other tumor types. |
|
| Publications: |
1 |
Organism: |
Homo Sapiens |
| + |
nivolumab | down-regulates activity
binding
|
PDCD1 |
0.4 |
| Identifier |
Residue |
Sequence |
Organism |
Cell Line |
| SIGNOR-259895 |
|
|
Homo sapiens |
Ovary Cancer Cell |
| pmid |
sentence |
| 26351349 |
Nivolumab is an anti-PD-1 antibody that blocks PD-1 signaling. We assessed the safety and antitumor activity of nivolumab in patients with platinum-resistant ovarian cancer. |
|
| Publications: |
1 |
Organism: |
Homo Sapiens |
| + |
PDCD1 | down-regulates activity
|
MEK1/2 |
0.268 |
| Identifier |
Residue |
Sequence |
Organism |
Cell Line |
| SIGNOR-275410 |
|
|
Homo sapiens |
T-lymphocyte |
| pmid |
sentence |
| 22740686 |
MEK1/2 was phosphorylated and activated upon activation of T cells through TCR-CD3 and CD28, which resulted in phosphorylation of its downstream target ERK1/2, as determined by Western blotting analysis with an antibody specific for ERK1/2 phosphorylated at Thr202 and Tyr204, markers of activation. PD-1 substantially inhibited the activation of MEK1/2 and ERK1/2 |
|
| Publications: |
1 |
Organism: |
Homo Sapiens |
| + |
PDCD1 | down-regulates activity
|
DNM1L |
0.2 |
| Identifier |
Residue |
Sequence |
Organism |
Cell Line |
| SIGNOR-275406 |
|
|
Homo sapiens |
T-lymphocyte |
| pmid |
sentence |
| 34535949 |
Mechanistically, we provided evidence that PD1 signaling downregulates Drp1 activating phosphorylation on Ser616 (and consequently mitochondrial fragmentation) via the inhibition of ERK1/2 and mTOR kinases. |
|
| Publications: |
1 |
Organism: |
Homo Sapiens |
| + |
PDCD1 | down-regulates activity
|
AKT |
0.352 |
| Identifier |
Residue |
Sequence |
Organism |
Cell Line |
| SIGNOR-275408 |
|
|
Homo sapiens |
T-lymphocyte |
| pmid |
sentence |
| 16227604 |
Akt phosphorylation in cells stimulated by CD3/CD28/CTLA-4 or CD3/CD28/PD-1 aAPCs did not have detectable phosphorylated Akt at any time point, indicating that CTLA-4 and PD-1 signaling blocked rather than delayed Akt activation. |
|
| Publications: |
1 |
Organism: |
Homo Sapiens |
3.0
PDCD1
- 
- 